EP0386232A4 - Nasal administration of benzodiazepine hypnotics - Google Patents

Nasal administration of benzodiazepine hypnotics

Info

Publication number
EP0386232A4
EP0386232A4 EP19890911428 EP89911428A EP0386232A4 EP 0386232 A4 EP0386232 A4 EP 0386232A4 EP 19890911428 EP19890911428 EP 19890911428 EP 89911428 A EP89911428 A EP 89911428A EP 0386232 A4 EP0386232 A4 EP 0386232A4
Authority
EP
European Patent Office
Prior art keywords
nasal administration
benzodiazepine hypnotics
benzodiazepine
nasal
hypnotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19890911428
Other versions
EP0386232B1 (en
EP0386232A1 (en
EP0386232B2 (en
Inventor
Arthur H. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribogene Inc
Original Assignee
Arthur H. Goldberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22925038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0386232(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arthur H. Goldberg filed Critical Arthur H. Goldberg
Publication of EP0386232A1 publication Critical patent/EP0386232A1/en
Publication of EP0386232A4 publication Critical patent/EP0386232A4/en
Publication of EP0386232B1 publication Critical patent/EP0386232B1/en
Application granted granted Critical
Publication of EP0386232B2 publication Critical patent/EP0386232B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Abstract

Nasal administration of benzodiazepines is described as providing improved therapeutic effects as compared to conventional delivery techniques. The compositions comprise a benzodiazepine hypnotic in a pharmaceutically acceptable nasal carrier.
EP89911428A 1988-09-16 1989-09-08 Nasal administration of benzodiazepine hypnotics Expired - Lifetime EP0386232B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/245,031 US4950664A (en) 1988-09-16 1988-09-16 Nasal administration of benzodiazepine hypnotics
US245031 1988-09-16
PCT/US1989/003897 WO1990002737A1 (en) 1988-09-16 1989-09-08 Nasal administration of benzodiazepine hypnotics

Publications (4)

Publication Number Publication Date
EP0386232A1 EP0386232A1 (en) 1990-09-12
EP0386232A4 true EP0386232A4 (en) 1991-03-13
EP0386232B1 EP0386232B1 (en) 1995-08-02
EP0386232B2 EP0386232B2 (en) 2000-09-06

Family

ID=22925038

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89911428A Expired - Lifetime EP0386232B2 (en) 1988-09-16 1989-09-08 Nasal administration of benzodiazepine hypnotics

Country Status (12)

Country Link
US (1) US4950664A (en)
EP (1) EP0386232B2 (en)
JP (1) JP2729525B2 (en)
KR (1) KR920005965B1 (en)
AT (1) ATE125799T1 (en)
AU (1) AU640618B2 (en)
CA (1) CA1336502C (en)
DE (1) DE68923697T3 (en)
DK (1) DK175710B1 (en)
IL (1) IL91656A0 (en)
NZ (1) NZ230653A (en)
WO (1) WO1990002737A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36744E (en) * 1988-09-16 2000-06-20 Ribogene, Inc. Nasal administration of benzodiazepine hypnotics
JP3219096B2 (en) * 1990-05-10 2001-10-15 ニコメド ファーマ エイエス Pharmaceutical preparations containing n-glycolfurols and n-ethylene glycols
US5166202A (en) * 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
CA2055308A1 (en) * 1990-11-29 1992-05-30 Roman Amrein Imidazobenzodiazepine for the treatment of sleep disorders
US5679580A (en) * 1994-03-09 1997-10-21 Midwest Research Institute Rapid evaporation method for analysis
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
EP0785788B1 (en) * 1994-10-14 2001-12-12 GLAXO WELLCOME S.p.A. Use of cck-b receptor antagonists for the treatment of sleep disorders
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
DE60038738T2 (en) * 1999-07-26 2009-07-02 Sk Holdings Co., Ltd. TRANSNASAL ANTICONVULSIVE COMPOSITIONS
PT1464641E (en) * 1999-12-30 2008-07-01 Lundbeck & Co As H 4-phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine d4 antagonists
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
AU2001286518A1 (en) * 2000-08-15 2002-02-25 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
DE60230035D1 (en) * 2001-05-24 2009-01-08 Alexza Pharmaceuticals Inc ADMINISTRATION OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM OR TRIAZOLAM BY INHALATION
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7138107B2 (en) * 2003-02-18 2006-11-21 Compellis Pharmaceuticals Inhibition of olfactory neurosensory function to treat eating disorders and obesity
US20040241100A1 (en) * 2003-03-17 2004-12-02 Fabre Kramer Pharmaceutical, Inc. Nasally administrable compositions of zolpidem and methods of use
CN100421649C (en) * 2003-06-17 2008-10-01 Sk株式会社 Transnasal microemulsions containing diazepam
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060039869A1 (en) * 2004-08-17 2006-02-23 Daniel Wermeling Intranasal delivery of antipsychotic drugs
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2009027697A2 (en) * 2007-08-31 2009-03-05 Archimedes Development Limited Non-aqueous pharmaceutical compositions
KR101517415B1 (en) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
EP2694076A4 (en) * 2011-04-01 2014-08-27 Cpex Pharmaceuticals Inc Nasal formulations of benzodiazepine
JP2016171366A (en) * 2015-03-11 2016-09-23 キヤノン株式会社 Image reading device
BR112018071082A2 (en) * 2016-04-14 2019-02-05 Paion Uk Ltd nasal and orally inhaled benzodiazepines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005210A1 (en) * 1986-03-10 1987-09-11 Kurt Burghart Pharmaceutical preparation and process for preparing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906265A (en) † 1957-09-03 1959-09-29 Maryland Devices Inc Nasal adaptor for valved dispenser
US4153689A (en) † 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1604644A (en) * 1977-07-22 1981-12-09 Wellcome Found Biologically active pentapeptide amides
US4284648A (en) * 1979-08-03 1981-08-18 The University Of Kentucky Research Foundation Nasal administration of propranolol
US4381773A (en) † 1980-06-23 1983-05-03 Schering Corporation Method and nozzle for nasal vaccination of immature mammals
US4428883A (en) * 1981-03-06 1984-01-31 The University Of Kentucky Research Foundation Novel method of administering β-blockers and novel dosage forms containing same
FR2568773B1 (en) * 1984-08-10 1989-03-03 Sandoz Lab NEW NASAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS
JPS6160620A (en) * 1984-09-03 1986-03-28 Teijin Ltd Pharmaceutical composition containing pyroglutamic acid ester
AU5063885A (en) * 1984-10-23 1986-05-15 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
JPS61267528A (en) † 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd Transnasal calcitonin agent containing absorbefacient
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005210A1 (en) * 1986-03-10 1987-09-11 Kurt Burghart Pharmaceutical preparation and process for preparing the same

Also Published As

Publication number Publication date
DE68923697D1 (en) 1995-09-07
IL91656A0 (en) 1990-04-29
AU640618B2 (en) 1993-09-02
NZ230653A (en) 1991-05-28
CA1336502C (en) 1995-08-01
DK120390A (en) 1990-05-15
ATE125799T1 (en) 1995-08-15
DE68923697T2 (en) 1996-01-25
DE68923697T3 (en) 2001-04-05
EP0386232B1 (en) 1995-08-02
AU4349989A (en) 1990-04-02
EP0386232A1 (en) 1990-09-12
JPH03501390A (en) 1991-03-28
DK120390D0 (en) 1990-05-15
JP2729525B2 (en) 1998-03-18
DK175710B1 (en) 2005-01-31
KR920005965B1 (en) 1992-07-25
US4950664A (en) 1990-08-21
KR900701252A (en) 1990-12-01
EP0386232B2 (en) 2000-09-06
WO1990002737A1 (en) 1990-03-22

Similar Documents

Publication Publication Date Title
EP0386232A4 (en) Nasal administration of benzodiazepine hypnotics
MX9700081A (en) Tacrine pharmaceutical compositions.
ZA928771B (en) Combination chemotherapy
MY119365A (en) Novel pharmaceutical combination
GR1000932B (en) Dosage form for administering oral hupoglycemic glipizide
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
EP0242643A3 (en) Nasal administration of drugs
IL76932A0 (en) Pharmaceutical compositions containing dihydrocodeine and ibuprofen
EP0830369A4 (en) Novel nor-pregnanes for inducing hypothalamic effects
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
IL91706A (en) Pharmaceutical compositions comprising in separate dosage form a plasminogen activator and hirudin
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
HUP9900751A3 (en) Stable pharmaceutical forms of administration containing parathormone
MY113203A (en) Lyophilizate of lipid complex of water insoluble camptothecins
NZ237930A (en) Wafer for administration of medicaments through the sub-lingual mucosa
IE860785L (en) Composition for delivery of orally administered drugs
GB2305606B (en) Drug delivery composition for the nasal administration of ICAM-1
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
AU2908389A (en) Device for administering medicaments by atomization in intubated or tracheotomized patients
MY101916A (en) Etoposide oral dosage form.
ZA872676B (en) Composition containing angiogenically active lipid containing molecules and a pharmaceutically acceptable carrier
EP0468327A3 (en) Oral pharmaceutical compositions containing hirudin
ZA978879B (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders.
GB9420748D0 (en) 1,5 benzodiazepine derivatives
DE3376327D1 (en) Spiro(2h-1,4-benzodioxepin-3(5h)4'-piperidine and 3'-pyrrolidino) compounds, a process for preparing the same and their use as medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19900822

A4 Supplementary search report drawn up and despatched

Effective date: 19910123

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930222

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RIBOGENE, INC.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 125799

Country of ref document: AT

Date of ref document: 19950815

Kind code of ref document: T

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

ET Fr: translation filed
REF Corresponds to:

Ref document number: 68923697

Country of ref document: DE

Date of ref document: 19950907

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

26 Opposition filed

Opponent name: PEPTECH (EUROPE) A/S

Effective date: 19960502

NLR1 Nl: opposition has been filed with the epo

Opponent name: PEPTECH (EUROPE) A/S

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLAW Interlocutory decision in opposition

Free format text: ORIGINAL CODE: EPIDOS IDOP

PLAW Interlocutory decision in opposition

Free format text: ORIGINAL CODE: EPIDOS IDOP

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20000906

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REG Reference to a national code

Ref country code: CH

Ref legal event code: AEN

Free format text: MAINTIEN DU BREVET DONT L'ETENDUE A ETE MODIFIEE

NLR2 Nl: decision of opposition
ET3 Fr: translation filed ** decision concerning opposition
ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

NLR3 Nl: receipt of modified translations in the netherlands language after an opposition procedure
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20050904

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050906

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050907

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050909

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20050913

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050914

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050919

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20050928

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20051125

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060930

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060930

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070403

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060908

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20070401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060908

BERE Be: lapsed

Owner name: *RIBOGENE INC.

Effective date: 20060930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070908